Learning Center

Your central location for online learning and education surrounding all aspects of tissue donation, tissue banking, research and transplantation.

Regenerative Medicine & The Future of Biotech (Group)


Back to Package

Bronchopleural fistula (BPF) is an abnormal opening between the airway and pleural cavity, causing serious, sometimes fatal, infection and other complications. It is a complication of thoracic surgery occurring in 1.4%-14% of patients and can be associated with high mortality (up to 50%), often requiring multiple procedures, prolonged hospitalization, and very poor quality of life.

There is no standardized treatment for BPF. Literature reports describe the preliminary use of mesenchymal stem cells (MSCs) as a potential treatment. The inclusion of a biologically relevant extracellular matrix (ECM) scaffold seeded with MSCs, may offer a considerable improvement in treatment outcomes compared to MSCs alone, particularly for large (more serious) BPF defects. 

Using a tissue-engineered approach Videregen’s proprietary solution combines and builds on the reported use of ECM scaffolds and MSCs to provide an innovative option for curative treatment of BPF, reducing morbidity, mortality, and prolonged hospitalization costs. 

Project goals
1. Generate human safety and efficacy data to support the future transition to pivotal clinical trials and eventual marketing authorization
2. Establish tissue engineering approaches/solutions using tissue scaffolds and cells as a viable and effective regenerative clinical solution
3. Develop and investigate the science underpinning the regenerative processes and mechanisms of tissue engineering

Dr. Steve Bloor

Dr. Bloor (CEO Videregen Limited) has over 30 years of experience in medical devices and regenerative medicine, with key expertise and leadership in strategic R&D, clinical compliance, and regulation specific to these areas having worked in US multinationals (J&J, Covidien/Medtronic) and UK start-up companies.

Formerly Chief Scientific Officer at Tissue Science Laboratories (TSL) plc., where Dr Bloor led the development of TSL’s unique regenerative tissue-based technology which was successfully commercialized in the EU, USA and Australasia. TSL listed on the Alternative Investment Market (AIM) via IPO, and was subsequently acquired by Covidien/Medtronic where Dr. Bloor became Vice President of R&D.

After the integration of TSL technology into Covidien/Medtronic, Dr. Bloor founded Videregen with a spin-out of world-leading tissue engineering IP from UK research organizations. Via angel investment and regional VC’s leveraged by UK and European Horizon 2020 grants, Dr. Bloor has led Videregen through preclinical and manufacturing development, and regulatory approval with the first human clinical trial imminent.

Key:

Complete
Failed
Available
Locked
Regenerative Med & The Future of Biotech
Select the "View On-Demand Recording" button to begin.
Select the "View On-Demand Recording" button to begin.
Presentation Survey
6 Questions
Certificate of Attendance
No credits available  |  Certificate available
No credits available  |  Certificate available